Panacos Pharmaceuticals, Inc.
PANC · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.00 | -0.00 |
| FCF Yield | -740.34% | -148.81% | -91.37% | -1,528.07% |
| EV / EBITDA | 0.38 | 0.31 | 1.58 | 0.35 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.83 | 0.78 | 0.37 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -44.43% | -40.33% | -0.90% | -31.85% |
| Free Cash Flow Growth | -3.10% | -38.32% | -121.30% | -148.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 0.80 | 2.18 | 0.40 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 298.08 | 84.82 | 135.35 | 76.44 |